Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
NCT01664676 on ClinicalTrials.gov · last registry update 2014-02-28
A small phase 4 — 11 participants, against a typical 75. The sponsor logged completion for February 2014. Primary outcome, as filed: Glomerular Filtration Rate (51Cr-EDTA plasma clearance). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- University of Aarhus
- Sponsor type
- Other
- Enrollment
- 11
- Started
- 2012-12
- Primary completion
- 2014-02 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Glomerular Filtration Rate (51Cr-EDTA plasma clearance)
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.